Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...

For decades, scientists have known that mitochondria, which produce energy inside our cells, malfunction in Parkinson's ...

Secures FDA Type C Meeting To Advance Parkinson's Disease Dementia Program. Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases ...

Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people ...

Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people ...

The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for Buntanetap in PDD. ・According to Annovis, PDD affects approximately 30% of ...

Across the UK, 166,000 people are living with Parkinson’s, with this figure projected to double by 2050.1,2 Ahead of the ...

For decades, scientists have known that mitochondria, which produce energy inside our cells, malfunction in Parkinson's ...

Kinesia paradoxa, a remarkable phenomenon, reminds us that when we feel stuck, the brain is often just waiting for the right cue to unlock a hidden pathway.

For all the advancements we have made in the medical field, there remains an essential dimension of health that we rarely ...